Kimberlee Trzeciak Deputy Commissioner for Policy, Legislation, and International Affairs of FDA | Official Website
Kimberlee Trzeciak Deputy Commissioner for Policy, Legislation, and International Affairs of FDA | Official Website
This is a 50% increase over the number of companies inspected in the previous quarter, when four companies received four inspections.
Most of the companies inspected at the time were involved in the Biologics and Devices sectors. Both the Drugs and Tobacco sectors sectors tied for second most common type.
There were four companies in line with FDA regulations that do not need to adjust their management operations or regulatory/administrative actions. Two should take voluntary action to correct their management operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.
| Company Name | Area of Business | Inspection Date | Result |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Drugs | 10/25/2024 | No Action Indicated (NAI) |
| Biomat Sciences, Inc. | Devices | 11/19/2024 | No Action Indicated (NAI) |
| Department of Defense - Navy | Biologics | 10/03/2024 | Voluntary Action Indicated (VAI) |
| Holy Cross of Silver Spring Blood Bank | Biologics | 10/22/2024 | No Action Indicated (NAI) |
| Master Sales, LLC | Tobacco | 11/21/2024 | Voluntary Action Indicated (VAI) |
| Tetracore, Inc. | Devices | 12/05/2024 | No Action Indicated (NAI) |
Alerts Sign-up